Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | May 11, 2026 | May 12, 2026 |
| Hims & Hers Health, Inc.HIMS · Entity 1878 | Director · Chief Policy Officer | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 93,660 |
Reported balance
After 2026-05-11 transaction · row 1
1 source rowRow 1 · 2026-05-11 · Sale · Disposed 34,819 · Balance 93,660 F1: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.27 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.27 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Hims & Hers Health, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 48,961 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 16,773 · Balance 48,961 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026 by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026 by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PARDES BIOSCIENCES, INC.
Report date August 31, 2023 · Filed August 31, 2023
Section 16 reporting ended · disclosed 2023-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-31 · Disposition to issuer · Disposed 37,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.94 · Expires 2031-07-31 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-31 · Disposition to issuer · Disposed 70,390 · Balance 0 F3: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.80 · Expires 2031-12-22 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F3: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2032-06-07 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-31 · Disposition to issuer · Disposed 37,500 · Balance 0 F3: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time).
F2: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.
F3: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | SaleClass A Common Stock | 16,773 | $27.85 | $467,128.05 |
DisclosureSEC source: 0001884671-26-000004 · wk-form4_1787257867.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,961 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026 by the Reporting Person. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:04 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 32,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000209 · wk-form4_1787087037.xml · derivative · entry 3 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,953 Underlying: Class A Common Stock · 32,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the Company's quarterly vesting dates, with the first such vesting date on March 15, 2026. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the Company's quarterly vesting dates, with the first such vesting date on March 15, 2026. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:04 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Tax withholdingClass A Common Stock | 16,147 | $28.15 | $454,538.05 |
DisclosureSEC source: 0001773751-26-000209 · wk-form4_1787087037.xml · nonDerivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,734 F2 · shares: The shares of Class A Common Stock were withheld by the issuer to cover tax withholding obligations in connection with the reported vesting and settlement of RSUs. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:04 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 32,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-26-000209 · wk-form4_1787087037.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:15 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 8,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000187 · wk-form4_1786738536.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,223 Underlying: Class A Common Stock · 8,223 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest in full on the first Company quarterly vesting date to occur after the earlier of (x) the date of the Company's next-occurring annual stockholder meeting or (y) the first anniversary of the grant date of the award. F1 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest in full on the first Company quarterly vesting date to occur after the earlier of (x) the date of the Company's next-occurring annual stockholder meeting or (y) the first anniversary of the grant date of the award. F1 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest in full on the first Company quarterly vesting date to occur after the earlier of (x) the date of the Company's next-occurring annual stockholder meeting or (y) the first anniversary of the grant date of the award. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 22:50 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 32,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000130 · wk-form4_1781736654.xml · derivative · entry 3 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,873 Underlying: Class A Common Stock · 32,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the Company's quarterly vesting dates, with the first such vesting date on March 15, 2026. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the Company's quarterly vesting dates, with the first such vesting date on March 15, 2026. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 22:50 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Tax withholdingClass A Common Stock | 15,396 | $30.17 | $464,497.32 |
DisclosureSEC source: 0001773751-26-000130 · wk-form4_1781736654.xml · nonDerivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,961 Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 22:50 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 32,919 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-26-000130 · wk-form4_1781736654.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:13 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 3,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000112 · wk-form4_1781557996.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:13 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 3,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-26-000112 · wk-form4_1781557996.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:10 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 34,819 | $12.94 | $450,557.86 |
DisclosureSEC source: 0001628280-26-034106 · wk-form4_1778616625.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,660 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.27 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:28 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 34,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032925 · wk-form4_1778272102.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. F2 · derivative.expiration_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:28 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 34,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-032925 · wk-form4_1778272102.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2026 Filed May 8, 2026 20:28 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 19,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032925 · wk-form4_1778272102.xml · derivative · entry 3 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,824 Underlying: Class A Common Stock · 19,824 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:29 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 32,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001884671-26-000002 · wk-form4_1773779345.xml · derivative · entry 3 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,792 Underlying: Class A Common Stock · 32,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a "Company Quarterly Vesting Date"), with the first such vesting date on March 15, 2026. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a "Company Quarterly Vesting Date"), with the first such vesting date on March 15, 2026. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:29 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Tax withholdingClass A Common Stock | 11,312 | $24.77 | $280,198.24 |
DisclosureSEC source: 0001884671-26-000002 · wk-form4_1773779345.xml · nonDerivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,782 F2 · shares: The shares of Class A Common Stock were withheld by the issuer to cover tax withholding obligations in connection with the reported vesting and settlement of RSUs. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:29 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 32,919 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001884671-26-000002 · wk-form4_1773779345.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:20 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 526,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-26-000047 · wk-form4_1773433244.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,711 Underlying: Class A Common Stock · 526,711 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a "Company Quarterly Vesting Date"), with the first such vesting date on March 15, 2026. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a "Company Quarterly Vesting Date"), with the first such vesting date on March 15, 2026. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:15 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | SaleClass A Common Stock | 7,054 | $36.71 | $258,952.34 |
DisclosureSEC source: 0001884671-25-000005 · wk-form4_1766092539.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,175 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025 by the Reporting Person. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:30 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 7,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-25-000382 · wk-form4_1765920650.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,110 Underlying: Class A Common Stock · 7,054 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on December 15, 2025, (ii) 1/3 of the RSUs vesting on December 15, 2026, and (iii) 1/3 of the RSUs vesting on December 15, 2027. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on December 15, 2025, (ii) 1/3 of the RSUs vesting on December 15, 2026, and (iii) 1/3 of the RSUs vesting on December 15, 2027. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:30 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 7,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-25-000382 · wk-form4_1765920650.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director · Chief Policy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:19 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 3,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-25-000267 · wk-form4_1754684379.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,656 Underlying: Class A Common Stock · 3,656 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. F1 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:38 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionRestricted Stock Unit · Derivative | 6,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-25-000205 · wk-form4_1750120726.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F1 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F1 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:38 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | Exercise / conversionClass A Common Stock | 6,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001773751-25-000205 · wk-form4_1750120726.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. Read SEC document |
| May 06, 2025 Filed May 8, 2025 23:10 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 34,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023998 · wk-form4_1746745819.xml · derivative · entry 3 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,819 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| May 05, 2025 Filed May 8, 2025 23:10 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-023998 · wk-form4_1746745819.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. F2 · derivative.expiration_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. Read SEC document |
| May 05, 2025 Filed May 8, 2025 23:10 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 40,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-023998 · wk-form4_1746745819.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 33,229 | $8.34 | $277,129.86 |
DisclosureSEC source: 0001628280-24-049149 · wk-form4_1732569962.xml · nonDerivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,402 F2 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 per share to $8.41 per share, inclusive. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 6,771 | $8.41 | $56,944.11 |
DisclosureSEC source: 0001628280-24-049149 · wk-form4_1732569962.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,631 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.38 to $8.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:12 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 6,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-24-000367 · wk-form4_1732057922.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,175 Underlying: Class A Common Stock · 6,175 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F3 · derivative.exercise_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. F3 · derivative.expiration_date: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2025 annual meeting of stockholders or (b) June 15, 2025. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:12 UTC | Hims & Hers Health, Inc. HIMS · Entity 1878 | GrantRestricted Stock Unit · Derivative | 21,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001773751-24-000367 · wk-form4_1732057922.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,164 Underlying: Class A Common Stock · 21,164 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on December 15, 2025, (ii) 1/3 of the RSUs vesting on December 15, 2026, and (iii) 1/3 of the RSUs vesting on December 15, 2027. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 3-year period, with (i) 1/3 of the RSUs vesting on December 15, 2025, (ii) 1/3 of the RSUs vesting on December 15, 2026, and (iii) 1/3 of the RSUs vesting on December 15, 2027. Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:10 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 23,447 | $6.73 | $157,727.97 |
DisclosureSEC source: 0001628280-24-024342 · wk-form4_1716235819.xml · nonDerivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,402 F1 · shares: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.77 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:10 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 14,553 | $6.76 | $98,378.28 |
DisclosureSEC source: 0001628280-24-024342 · wk-form4_1716235819.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,849 F1 · shares: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.79 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:45 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-023258 · wk-form4_1715719474.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:45 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 76,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023258 · wk-form4_1715719474.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 02, 2024 Filed May 6, 2024 21:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 40,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020719 · wk-form4_1715030386.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:32 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $5.21 | Not disclosed |
DisclosureSEC source: 0001209191-23-047815 · doc4.xml · derivative · entry 4 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2032-06-07 F3 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F3 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F3 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:32 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $9.80 | Not disclosed |
DisclosureSEC source: 0001209191-23-047815 · doc4.xml · derivative · entry 3 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2031-12-22 F3 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F3 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F3 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:32 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,390 | Not disclosed Strike: $4.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-047815 · doc4.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,390 shares Expires 2031-07-31 F3 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F3 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F3 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:32 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-047815 · doc4.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2033-05-31 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 54,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043988 · doc4.xml · derivative · entry 2 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 54,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On July 29, 2022 the reporting person was granted 54,949 restricted stock units vesting on July 30, 2023. F2 · derivative.expiration_date: On July 29, 2022 the reporting person was granted 54,949 restricted stock units vesting on July 30, 2023. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 54,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043988 · doc4.xml · nonDerivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:05 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-23-033658 · doc4.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2033-05-31 F1 · derivative.exercise_date: Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 76,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028736 · doc4.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,453 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| July 29, 2022 Filed Aug 3, 2022 01:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 54,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044013 · doc4.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,949 Underlying: Class A Common Stock · 54,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:21 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001209191-22-035886 · doc4.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2032-06-07 F1 · derivative.exercise_date: Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:30 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0000899243-21-049931 · doc4.xml · derivative · entry 1 Autor Deborah M. · CIK 0001884671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-22 F1 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over three years, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.